KR20170037025A - Primer for Beta2-Microglobulin gene remove using CRISPR/CAS9 system - Google Patents
Primer for Beta2-Microglobulin gene remove using CRISPR/CAS9 system Download PDFInfo
- Publication number
- KR20170037025A KR20170037025A KR1020150136069A KR20150136069A KR20170037025A KR 20170037025 A KR20170037025 A KR 20170037025A KR 1020150136069 A KR1020150136069 A KR 1020150136069A KR 20150136069 A KR20150136069 A KR 20150136069A KR 20170037025 A KR20170037025 A KR 20170037025A
- Authority
- KR
- South Korea
- Prior art keywords
- crispr
- beta
- primer
- gene
- microglobulin
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Abstract
The method for removing the beta 2 -microglobulin gene using the CRISPR / CAS9 system of the present invention and the primer used therein are specifically designed so that only the beta 2 -microglobulin gene is selectively and selectively removed, Only the beta 2 -microglobulin gene, which is a gene, is specifically and accurately removed, thereby remarkably improving the removal efficiency.
Description
The present invention relates to a primer for the removal of a beta 2-microglobulin gene using the CRISPR / CAS9 system.
Since the discovery of restriction enzymes that recognize and cut specific sequences of DNA in the 1970s, genetic engineering techniques have developed rapidly over time. However, the limitation of gene manipulation technology using restriction enzymes was clear. Specifically, the restriction enzyme has a short length of about 6 to 8 recognizable gene sequences, and there is a problem that only about 46 (4,096) ordered pairs can be distinguished. The CRISPR / CAS9 system, on the other hand, does not have this limitation and is theoretically applicable to higher life than human beings.
The CRISPR / CAS9 system is a genome editing method called a clustered regularly interspaced short palindromic repeat (CRISPR) gene scissors. It uses RNA (gRNA) that specifically binds to a specific nucleotide sequence and Cas9 nuclease . Using such a CRISPR / CAS9 system, it is possible to knock-out plasmids into cells or animals to inhibit the function of specific genes.
The CRISPR / CAS9 system was discovered by scientists only a few years ago, and is a very old way of organisms, such as bacteria, that keep themselves from bacteriophages. An organism has evolved over millions of years by cutting off the bacteriophage's DNA, sticking it to its own gene, and surviving through adaptive immunity, which has been studied in a simple and clear way to quickly edit the organism's DNA in the laboratory.
Specifically, the original CRISPR / CAS9 system stores a portion of the DNA of a virus previously infected by the bacteria in its own genome, then retrieves the information again when the virus invades, Protection mechanism. By using it in genome engineering, a primer that searches for the base sequence of a specific gene is made and paired with the enzyme Cas9, which is a cleavage enzyme, to cling to the target DNA sequence to cause DNA cleavage. Therefore, mutation occurs in DNA repair (repair) process.
Until the CRISPR / CAS9 system was discovered, DNA editing was possible only with a sophisticated laboratory, many years of experience, a huge amount of money, and a very small range that could be practically applied. However, the CRISPR / Resolved.
Accordingly, the CRISPR / CAS9 system is highly expected to be a tool for the development of stem cell and somatic cell mutations that cause genetic diseases or the development of therapeutic agents for cancer cells.
As a result, the CRISPR / CAS9 system is inexpensive and easy to use, making it a revolution in genetic research. Large-scale research institutes are gradually building up patents related to christopher, and are investing heavily in research funding in the public and private sectors as well as the Crisper project.
However, there are still many problems in applying the CRISPR / CAS9 system to the human body. For example, in order to effectively utilize the CRISPR / CAS9 system in the human body, safety is very important, specifically, the target gene must be definitely removed and genes other than the target gene should not be affected. This is because the CRISPR / CAS9 system is likely to cause mutations in non-target nucleotide sequences similar to the nucleotide sequence of the target gene, and this possibility should eliminate the risk or potential risk of unforeseen mutations or unanticipated fatal problems .
In particular, the technology using the CRISPR / CAS9 system for deliberately editing genes that are specific to target genes is complex and difficult. Therefore, in order to clarify the causative mechanism of human diseases including tumors, and to use the CRISPR / CAS9 system as a whole in the human body, it should be applied exclusively to the target gene.
Therefore, in order to identify the Beta2-microglobulin (B2MG) gene using the CRISPR / CAS9 system or to prevent the beta 2-microglobulin gene from being expressed without ultimately affecting other gene sequences, And a condition using a CRISPR / CAS9 system suitable for the primer is required.
In order to solve the above problems, an object of the present invention is to provide a primer for beta2-microglobulin gene deletion using a CRISPR / CAS9 system in which only a beta 2-microglobulin gene is specifically and specifically removed.
It is another object of the present invention to provide a primer for the removal of a beta 2 -microglobulin gene using a CRISPR / CAS9 system in which only the target gene, beta 2-microglobulin gene, is specifically and correctly removed without affecting non-target genes will be.
The present invention provides a primer for the removal of a Beta2-Microglobulin gene using a CRISPR / CAS9 system, which is a forward primer of SEQ ID NO: 1.
The present invention provides a primer for beta2-microglobulin gene deletion using the CRISPR / CAS9 system, which is a reverse primer of SEQ ID NO: 2.
The present invention also provides a method for preparing a plasmid comprising the steps of: a) inserting a primer of SEQ ID NOs: 1 and 2 into a plasmid to which a CRISPR / CAS9 system is applied, b) transforming the plasmid into which the primer of step a) has been inserted into a competent cell And c) transfection of the transfected water-soluble cells of step b) into a target cell to remove the beta 2 -microglobulin gene. The method of
In one example of the present invention, a target therapeutic agent, an assay kit or a gene removal kit including a primer for removing a beta 2-microglobulin gene using the CRISPR / CAS9 system can be provided.
In one example of the present invention, a gene therapy method including a beta 2-microglobulin gene removal method using the CRISPR / CAS9 system can be provided.
The primer for the removal of the beta 2 -microglobulin gene using the CRISPR / CAS9 system of the present invention is specially designed so that only the beta 2 -microglobulin gene can be selectively and selectively removed so that the target gene beta 2 - There is an effect that only the microglobulin gene is specifically and correctly removed and the removal efficiency is remarkably improved.
FIG. 1 is a graph showing the results of electrophoretic bands and direct sequence analysis of the primers of SEQ ID NOS: 1 and 2 of the present invention according to Example 1 inserted into a plasmid and the plasmid. FIG.
FIG. 2 is a graph showing the relative intensity of the beta 2 -microglobulin gene by Western blot analysis of the transfected cells according to Example 1. FIG.
Fig. 3 is a graph showing the results of the transfection in accordance with Example 1 (B2M), Comparative Example 1 (B2M-2), Comparative Example 2 (B2M-3), Comparative Example 3 (B2M-4), and Comparative Example 4 And the relative intensities of bands of beta-2-microglobulin genes measured by Western blotting the target cells.
Hereinafter, a primer for beta2-microglobulin gene deletion using the CRISPR / CAS9 system of the present invention will be described in detail with reference to the accompanying drawings.
The drawings described in the present invention are provided by way of example so that a person skilled in the art can sufficiently convey the idea of the present invention. Therefore, the present invention is not limited to the illustrated drawings, but may be embodied in other forms, and the drawings may be exaggerated in order to clarify the spirit of the present invention.
In addition, unless otherwise defined, technical terms and scientific terms used in the present invention have the same meanings as those of ordinary skill in the art to which the present invention belongs. In the following description and the accompanying drawings, Description of known functions and configurations that may unnecessarily obscure the subject matter will be omitted.
Also, units of% used unclearly in the present invention means weight percent.
Until now, there have been various problems in applying the CRISPR / CAS9 system to the human body. For example, the CRISPR / CAS9 system is likely to mutate in a non-target base sequence similar to that of the target gene. In particular, But it is difficult to elaborate genetically.
Accordingly, in order to solve the above problems, the present invention provides a gene deletion method using a CRISPR / CAS9 system, that is, a target gene is selectively and selectively removed by knock-out, thereby effectively suppressing the expression of the target gene- A method for removing beta-2-microglobulin gene using a CRISPR / CAS9 system and a primer used therefor. Therefore, by specifically designing the primer so that only the target gene is selectively and precisely removed, the beta 2-microglobulin gene removal efficiency is remarkably improved.
In one embodiment of the present invention, a method for removing a beta 2-microglobulin gene using a CRISPR / CAS9 system comprises the steps of: a) inserting a primer of SEQ ID NOS: 1 and 2 into a plasmid to which a CRISPR / CAS9 system is applied, b) Transforming the plasmid into a competent cell; and c) transfecting the transfected water-soluble cells of step b) into a target cell to produce beta-2-microglobulin And removing the gene.
The forward primer of SEQ ID NO: 1 of the present invention is CACCGACCCAGACACATAGCAATTC.
The reverse primer of SEQ ID NO: 2 of the present invention is AAACGAATTGCTATGTGTCTGGGTC.
In one example of the present invention, the forward primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 may contain one or more base sequences complementary to a part of the beta 2-microglobulin base sequence. In general molecular biotechnology, when a primer designed randomly or arbitrarily is used as a complementary base sequence of a gene to be subjected to, it may not be a problem because it can be recognized and acted on. However, the use of a CRISPR / CAS9 system for beta 2-microglobulin In the case of the gene removal method, as described above, there is a problem that only the target 2-microglobulin gene is specifically and precisely removed. However, since the forward primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 of the present invention are all applied to the CRISPR / CAS9 system, only the beta 2 -microglobulin gene can be specifically and accurately removed. In addition, since it does not affect the non-target gene, the mutation does not occur even in a similar non-target base sequence, for example, and the stability is remarkably improved.
As described above, the forward primer of SEQ ID NO: 1 of the present invention and the reverse primer of SEQ ID NO: 2 are applied to the method for removing the beta 2-microglobulin gene using the CRISPR / CAS9 system, And the expression of the property by the beta-2-microglobulin gene is suppressed by knocking out the gene selectively and correctly. Therefore, it can be actively used to identify the role of the beta 2 -microglobulin gene, and ultimately, it can be applied to and applied to the development of beta 2-microglobulin target therapeutic agent in tumors. Specifically, a target therapeutic agent, an assay kit or a gene removal kit including a primer for removing a beta 2 -microglobulin gene using the CRISPR / CAS9 system of the present invention can be exemplified. And a gene therapy method (tumor treatment method and the like) including a 2-microglobulin gene removal method.
In one example of the present invention, the plasmid of step a) is not limited as long as it is a plasmid to which the CRISPR / CAS9 system is applied. For example, pX330-U6-Chimeric_BB-CBh-hSpCas9 shown in FIG. 1 is exemplified . When the plasmid of FIG. 1 is used in the method for removing the beta 2 -microglobulin gene using the CRISPR / CAS9 system of the present invention, the forward primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 of the present invention, , And then the water-soluble cells containing the plasmid can be selectively cultured and effectively cultured in the step b). In addition, since the transfection efficiency can be further improved in the target cell in the step c) Do. However, this is a preferable example, but the present invention is not limited thereto.
In one embodiment of the present invention, the target cell in step c) comprises a beta 2 -microglobulin gene sequence or a beta 2 -microglobulin gene, or the presence or absence of the characteristic (HCT-116 or the like) can be exemplified, as long as it is a target for human colon cancer, or is used for research such as characterization and role identification as a living body model.
Hereinafter, the method for removing the beta-2-microglobulin gene using the CRISPR / CAS9 system of the present invention will be described in detail, but the steps or processes described below are not limited to the present invention.
In one embodiment of the present invention, the step a) may include inserting the primers of SEQ ID NOS: 1 and 2 into a plasmid to which the CRISPR / CAS9 system is applied.
A) isolating a portion of the plasmid by cleaving a portion of the plasmid with a restriction enzyme, a2) dephosphorylating the isolated plasmid by truncating the fragment, and a3) isolating the plasmid from SEQ ID NOs: 1 and 2 Annealing the primers and ligation to the dephosphorylated plasmid.
In one embodiment of the present invention, the step b) may include transforming a plasmid into which the primer of the step a) has been inserted into a water-soluble cell. Thus, the plasmid into which the primers of the present invention are inserted is transformed into a water-soluble cell, thereby allowing transformation into the target cell in step c). In addition, the water-soluble cells containing the plasmid can be amplified through a process such as culture by the step b). In addition, water-soluble cells containing the plasmid can be obtained by additionally carrying out a step of selecting, using an infection strain, a step of transforming the water-soluble cells with a plasmid containing a gene sequence expressing the infectious immunological characteristic . Also, the beta-2-microglobulin gene is removed by transfection of the plasmid into the target cell of step c), whereby the direct / indirect characteristic of the organism including the target cell or the target cell by beta 2 -microglobulin Expression can be suppressed.
As a specific example, it may further comprise the step of selecting the cells transformed with the plasmid between step b) and step c). For example, by using a plasmid in advance to contain a gene sequence that expresses the infectious immunity characteristic using an infectious strain such as Carbenicillin, the water-soluble cells containing the plasmid in which the inventive primers are inserted are selectively sorted And amplified.
In one embodiment of the present invention, the step c) may include a step of transfecting a plasmid into a target cell. Methods for transfecting a plasmid into which the primers of the present invention are inserted into a target cell can be used without limitation because there are various known methods.
As described above, in the case of using the forward primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 and the beta 2-microglobulin gene removal method using the CRISPR / CAS9 system, only the beta 2 -microglobulin gene is specifically Can be selectively and finely removed. For example, it can be used to identify the role of beta 2-microglobulin in a variety of human-derived cell lines and zebrafish, and ultimately the development of beta 2-microglobulin target therapeutic agents (beta 2- Microglobulin gene target therapeutic agents, gene removal kits, gene analysis kits, etc.).
Hereinafter, the present invention will be described in detail with reference to Examples. However, the present invention is described in more detail with reference to the following Examples. However, the scope of the present invention is not limited by the following Examples.
The site of the plasmid (pX330-U6-Chimeric_BB-CBh-hSpCas9) to which the restriction enzyme was applied was cleaved using BbsI restriction enzyme and then isolated. Specifically, 2 μl of NEB buffer 2.1, 1 μl of BbsI, 5.1 μl of plasmid and 11.9 μl of distilled water (DW) were incubated at 37 ° C. for 2 hours, followed by electrophoresis (1 μl loading) PCR purification was performed using a kit.
Next, the isolated plasmid DNA (DNA of plasmid) was dephosphorylated. Specifically, 17 μl of DNA of plasmid, 1 μl of Shrimp alkaline phosphatase (SAP) and 2 μl of SAP 10x buffer were reacted at 37 ° C for 5 minutes and then reacted at 65 ° C for 5 minutes.
Next, the forward primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 were annealed. Specifically, 1 μl of each primer, 3 μl of H + buffer, and 45 μl of distilled water were reacted at 100 ° C. for 3 minutes and then reacted at 70 ° C. for 5 minutes.
Next, the forward primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 annealed to the separated pX330-U6-Chimeric_BB-CBh-hSpCas9 were inserted (Ligation). Specifically, 1 μl of DNA of plasmid, 0.5 μl of each primer, 1.5 μl EB buffer, and 3 μl of Mighty Mix were reacted at room temperature for 12 minutes.
Next, the plasmid DNA into which the primer was inserted was transformed into a competent cell. Specifically, 6 μl of plasmid DNA with a primer inserted into 50 μl of competent cells of DHα was reacted on ice for 20 minutes, followed by reaction in a water bath of 42 ° C. for 90 seconds, followed by reaction on ice for 2 minutes . Subsequently, 150 μl of LB broth was dispensed, and then cultured in a 37 ° C water bath for 30 minutes. Subsequently, 150 μl of the cultured mixture was spread on a LB solid medium containing Carbenicillin, and then cultured in a 37 ° C. incubator for 12 hours. Then, 8 colonies were selected from the solid medium, and each of them was dissolved in LB broth (40 ml of LB broth, carbenicillin 40 μl) containing carbenicillin, and then cultured in a 37 ° C. shaker incubator for 12 hours . Plasmid DNA was extracted from the cultured mixture, and the transformation was confirmed by electrophoresis and direct sequence analysis. Specifically, 1 μl of NEB buffer, 1 μl of BSA (10 ×), and 1 μl of XbaI 0.4 (1 μl of NEB buffer) were obtained by cutting with restriction enzymes XbaI and SacII and confirming the electrophoretic phase band (7117 bp / 1392 bp) , 0.4 μl of Sac II, 1 μl of DNA of plasmid, and 6.2 μl of distilled water at 37 ° C for 1 hour)
Next, transfection was carried out using human-derived colon cancer cell line (HCT-116) as a target cell, and then it was confirmed by Western blot that the β 2 -microglobulin gene was properly removed. The results are shown in FIGS. 2 and 3 Respectively.
Specifically, the above-described transfection method is as follows. The frozen HCT-116 cell stock was thawed in a 37 ° C water bath and added to 4 ml of DMEM medium (10% FBS (HyClone, GE Healthcare Life Science, Logan, USA), 1% P / S) Lt; / RTI > for 5 minutes to remove supernatant. 10 ml of DMEM medium was further added thereto and cultured in a 100 mm dish for 12 hours. Subsequently, the medium was removed, washed with PBS, added with 2 ml of 0.5% trypsin, allowed to react for 5 minutes in an incubator (37 ° C in a 5% CO 2 incubator), and then added with 4 ml of DMEM medium The supernatant was removed by centrifugation at rpm for 5 minutes. After the new DMEM was added to the medium 7 ㎖ cell counting, 60 mm dish tissue culture plate in 3 × 10 6 / ㎖ (confluence 80%) by dividing the HCT-116 cell of the concentration, and then the incubator (5% CO at 2 incubator 37 Lt; 0 > C) for 12 hours. The medium of the cultured cells was replaced with 4 ml of DMEM medium supplemented with no P / S (antibiotics) and only FBS. Plasmid DNA, Lipofectamine 2000 (Invitrogen) and OPTI-MEM (Thermo Fisher Scientific) were prepared and 500 μl of OPTI-MEM medium was dispensed into each of the two EP tubes. 20 μl of Lipofectamine 2000 was added to No. 1 tube, After adding 8 ㎍ of plasmid DNA to the tube,
[Comparative Example 1]
(CACCGCATACTCATCTTTTTCAGT) containing the nucleotide sequence complementary to one part of the beta 2-microglobulin base sequence, respectively, instead of the forward primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 in Example 1 and the forward primer (AAACACTGAAAAAAGATGAGTATGC) was used as the reverse primer (AAACACTGAAAAAGATGAGTATGC). The results are shown in FIG.
[Comparative Example 2]
(CACCGCTACTCTCTTCTTTCTGGCC) having the nucleotide sequence complementary to a part of the beta 2-microglobulin base sequence, respectively, instead of the forward primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 in Example 1 and the forward primer (AAACGGCCAGAAAGAGAGAGTAGC) was used as the reverse primer (AAACGGCCAGAAAGAGAGAGTAGC), and the results are shown in FIG.
[Comparative Example 3]
(CACCGACATGTAAGCAGCATCATGG) containing a nucleotide sequence complementary to a part of the beta 2-microglobulin base sequence, respectively, instead of the forward primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 in Example 1 and the forward primer (AAACCCATGATGCTGCTTACATGTC) was used as the reverse primer (AAACCCATGATGCTGCTTACATGTC), and the results are shown in FIG.
[Comparative Example 4]
(CACCGTGTTTGATGTATCTGAGCAG) containing the nucleotide sequence complementary to a part of the beta 2-microglobulin nucleotide sequence in place of the forward primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 in Example 1 and the forward primer 10 of the reverse primer (AAACCTGCTCAGATACATCAAACAC) was used, and the results are shown in FIG.
1 shows the results of electrophoretic bands and direct sequencing analysis of the primers of SEQ ID NOS: 1 and 2 of the present invention according to Example 1 inserted into a plasmid and the plasmid, and the results of the plasmid using the plasmid with the CRISPR / CAS9 system The reverse primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 of the present invention were properly inserted into the primer.
FIG. 2 shows the relative intensity of the beta 2 -microglobulin gene measured by Western blotting the transfected target cells according to Example 1, confirming that the beta 2 -microglobulin gene was effectively removed have.
Fig. 3 is a graph showing the results of the transfection in accordance with Example 1 (B2M), Comparative Example 1 (B2M-2), Comparative Example 2 (B2M2-3), Comparative Example 3 (B2M-4) and Comparative Example 4 (B2M- The relative intensity of the beta 2-microglobulin gene was measured by Western blotting of the target cells. When using a random primer designed randomly or arbitrarily, of band is about twice that of the case where the primer of the present invention is used. From this, it can be seen that when the designed primer is used, only the target gene, beta 2-microglobulin gene, Can not be removed.
It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present invention as defined by the appended claims and their equivalents.
<110> Chonnam National University <120> Primer for Beta2-Microglobulin gene remove using CRISPR / CAS9 System <130> P15070970829 <160> 10 <170> KoPatentin 3.0 <210> 1 <211> 25 <212> DNA <213> Unknown <220> <223> Beta2-Microglobulin <400> 1 caccgaccca gacacatagc aattc 25 <210> 2 <211> 25 <212> DNA <213> Unknown <220> <223> Beta2-Microglobulin <400> 2 aaacgaattg ctatgtgtct gggtc 25 <210> 3 <211> 24 <212> DNA <213> Unknown <220> <223> Beta2-Microglobulin <400> 3 caccgcatac tcatcttttt cagt 24 <210> 4 <211> 24 <212> DNA <213> Unknown <220> <223> Beta2-Microglobulin <400> 4 aaacactgaa aaagatgagt atgc 24 <210> 5 <211> 24 <212> DNA <213> Unknown <220> <223> Beta2-Microglobulin <400> 5 caccgctact ctctctttct ggcc 24 <210> 6 <211> 24 <212> DNA <213> Unknown <220> <223> Beta2-Microglobulin <400> 6 aaacggccag aaagagagag tagc 24 <210> 7 <211> 25 <212> DNA <213> Unknown <220> <223> Beta2-Microglobulin <400> 7 caccgacatg taagcagcat catgg 25 <210> 8 <211> 25 <212> DNA <213> Unknown <220> <223> Beta2-Microglobulin <400> 8 aaacccatga tgctgcttac atgtc 25 <210> 9 <211> 25 <212> DNA <213> Unknown <220> <223> Beta2-Microglobulin <400> 9 caccgtgttt gatgtatctg agcag 25 <210> 10 <211> 24 <212> DNA <213> Unknown <220> <223> Beta2-Microglobulin <400> 10 caccgcatac tcatcttttt cagt 24
Claims (7)
b) transforming the plasmid in which the primer of step a) is inserted into a water-soluble cell; and
c) transforming the transfected water-soluble cells of step b) into a target cell to remove the beta-2-microglobulin gene,
/ RTI > a method for the removal of beta 2-microglobulin genes using the CRISPR / CAS9 system.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150136069A KR101795999B1 (en) | 2015-09-25 | 2015-09-25 | Primer for Beta2-Microglobulin gene remove using CRISPR/CAS9 system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150136069A KR101795999B1 (en) | 2015-09-25 | 2015-09-25 | Primer for Beta2-Microglobulin gene remove using CRISPR/CAS9 system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170037025A true KR20170037025A (en) | 2017-04-04 |
| KR101795999B1 KR101795999B1 (en) | 2017-11-09 |
Family
ID=58588335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150136069A KR101795999B1 (en) | 2015-09-25 | 2015-09-25 | Primer for Beta2-Microglobulin gene remove using CRISPR/CAS9 system |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101795999B1 (en) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
| US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
| US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
| US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
| US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
| US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150091052A (en) | 2012-12-06 | 2015-08-07 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-based genome modification and regulation |
-
2015
- 2015-09-25 KR KR1020150136069A patent/KR101795999B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150091052A (en) | 2012-12-06 | 2015-08-07 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-based genome modification and regulation |
Cited By (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
| US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
| US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
| US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
| US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
| US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
| US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
| US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
| US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
| US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101795999B1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101795999B1 (en) | Primer for Beta2-Microglobulin gene remove using CRISPR/CAS9 system | |
| KR101745863B1 (en) | Primer for prohibitin2 gene remove using CRISPR/CAS9 system | |
| US20200385697A1 (en) | Thermostable cas9 nucleases | |
| Jinek et al. | RNA-programmed genome editing in human cells | |
| CN112041444A (en) | Novel CRISPR DNA targeting enzymes and systems | |
| US10557151B2 (en) | Somatic human cell line mutations | |
| JP2021048882A (en) | Rna-guided human genome engineering | |
| KR102271292B1 (en) | Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing | |
| US11685935B2 (en) | Compact scaffold of Cas9 in the type II CRISPR system | |
| US11667904B2 (en) | CRISPR-associated systems and components | |
| CA3111432A1 (en) | Novel crispr enzymes and systems | |
| US11453867B2 (en) | CRISPR DNA targeting enzymes and systems | |
| US20210147915A1 (en) | Crispr/cas and transposase based amplification compositions, systems and methods | |
| CN114269912A (en) | Novel CRISPR DNA targeting enzymes and systems | |
| JP7210028B2 (en) | Gene mutation introduction method | |
| US11072782B2 (en) | Construct for epigenetic modification and its use in the silencing of genes | |
| US20220282283A1 (en) | Novel crispr dna targeting enzymes and systems | |
| JP2023539237A (en) | Systems and methods for transposing cargo nucleotide sequences | |
| RU2012146457A (en) | METHOD FOR SELECTION OF CELLS ABLE FOR LONG PRODUCTION | |
| US20240052337A1 (en) | Method for causing large-scale deletions in genomic dna and method for analyzing genomic dna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |